🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Solid will be participating in upcoming investor conferences, where President & CEO, Bo Cumbo, and CMO, Gabriel Brooks, M.D., will partake in fireside chats. - Leerink Partners Global Healthcare Conference: March 12, at 9:20 AM ET - Barclays Bank 27th Annual Global Healthcare

Solid Biosciences is pleased to announce our financial results for the fourth quarter and full year 2024, along with business updates. Read the full release: investors.solidbio.com/news-releases/… $SLDB

Solid will be presenting at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference, in Dallas, Texas, on Wednesday, March 19 at 1:45 PM CT / 2:45 PM ET. Learn more: investors.solidbio.com/news-releases/… #MDAConference $SLDB

Solid's leadership will be participating in upcoming investor conferences. 24th Annual Needham Virtual Healthcare Conference: Bo Cumbo, President and CEO, and Gabriel Brooks, Chief Medical Officer, will present on Thursday, April 10, at 2:15 PM ET. Watch the live webcast:

We’re proud to partner with the FA Research Alliance to host a live webinar on Tuesday, April 15 at 12 PM ET. Solid team members, Matthew Harmelink, MD, Therapeutic Head of Neuromuscular and child neurologist, and Annie Ganot, Co-founder and SVP of Patient Advocacy, will share insights

ICYMI: Craig McDonald, MD, Chair, Department of Physical Medicine & Rehabilitation, UC Davis Health and investigator in the INSPIRE DUCHENNE trial, shared his thoughts on the initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, our next-generation gene

Solid Biosciences will present three oral presentations, including one late-breaker, and four posters at #ASGCT2025, taking place May 13-17 in New Orleans. The data presentations will focus on our next-generation Duchenne muscular dystrophy program, SGT-003, the mechanisms of

Bo Cumbo, President and CEO of Solid Biosciences, will be participating in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, at 12:30 PM ET. Join via a live webcast: investors.solidbio.com/news-and-event… $SLDB

Our Head of Clinical Science, Patrick Gonzalez, Ph.D., will be presenting at the International Duchenne Congress Duchenne Parent Project España taking place May 2-4. Dr. Gonzalez will speak on SGT-003, highlighting the potential of our next-generation, investigational gene therapy for Duchenne

May is Friedreich’s Ataxia Awareness Month. #FriedreichsAtaxia (FA) is a rare, progressive genetic disease caused by mutations in the FXN gene, leading to reduced levels of frataxin – an essential protein for nerve and heart function. This month, we join the FA community in

Solid Biosciences is pleased to announce our financial results and business updates for the first quarter of 2025. Read the full release: investors.solidbio.com/news-releases/… $SLDB

Tomorrow is #FriedreichsAtaxia Awareness Day. At Solid Biosciences, we stand in solidarity with the FA community and are committed to making a difference. On this day and every day, we reaffirm our dedication to advancing SGT-212, our differentiated investigational gene therapy

Solid is proud to sponsor the CureDuchenne 2025 FUTURES National Conference in San Antonio, Texas, from May 22-25. On Friday, May 23 at 11:05 AM CT / 12:05 PM ET, our Head of Clinical Science, Patrick Gonzalez will be speaking in the Micro-dystrophin Gene Therapies session on

Solid Biosciences will participate in the Jefferies Global Healthcare Conference, where our President and CEO, Bo Cumbo, and Chief Medical Officer, Gabriel Brooks, M.D., will take part in a fireside chat at 2:00 PM ET. Join via a live webcast: investors.solidbio.com/news-and-event… $SLDB

Solid is heading to Parent Project Muscular Dystrophy (PPMD)’s 2025 Annual Conference in Las Vegas! Learn more about SGT-003, our next-generation, investigational gene therapy for Duchenne muscular dystrophy during the session, “Exploring the Landscape of Gene Therapy,” on Thursday, June 19. Stop by